BR9916893A - Tratamento - Google Patents

Tratamento

Info

Publication number
BR9916893A
BR9916893A BR9916893-6A BR9916893A BR9916893A BR 9916893 A BR9916893 A BR 9916893A BR 9916893 A BR9916893 A BR 9916893A BR 9916893 A BR9916893 A BR 9916893A
Authority
BR
Brazil
Prior art keywords
hepatitis
treatment
virus
vaccine
antiviral agent
Prior art date
Application number
BR9916893-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Gillian Frances Atkinson
Ronald James Boon
Pierre G Vandepapeliere
Martine Anne Cecil Wettendorff
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of BR9916893A publication Critical patent/BR9916893A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9916893-6A 1999-01-12 1999-12-21 Tratamento BR9916893A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12
PCT/EP1999/010295 WO2000041463A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Publications (1)

Publication Number Publication Date
BR9916893A true BR9916893A (pt) 2001-11-20

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916893-6A BR9916893A (pt) 1999-01-12 1999-12-21 Tratamento

Country Status (19)

Country Link
EP (1) EP1140163A2 (ja)
JP (1) JP2002534438A (ja)
KR (1) KR20010090011A (ja)
CN (1) CN1391482A (ja)
AR (1) AR022250A1 (ja)
AU (1) AU760574B2 (ja)
BR (1) BR9916893A (ja)
CA (1) CA2359110A1 (ja)
CO (1) CO5241355A1 (ja)
CZ (1) CZ20012544A3 (ja)
HK (1) HK1041434A1 (ja)
HU (1) HUP0105070A2 (ja)
IL (1) IL144186A0 (ja)
NO (1) NO20013337L (ja)
NZ (1) NZ512890A (ja)
PL (1) PL349347A1 (ja)
TR (1) TR200102024T2 (ja)
WO (1) WO2000041463A2 (ja)
ZA (1) ZA200105690B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US7030212B1 (en) 1998-07-31 2006-04-18 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
WO2003028758A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (es) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Terapia combinada para el tratamiento de la hepatitis b crónica
US20220088188A1 (en) * 2018-12-24 2022-03-24 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
JPWO2022215737A1 (ja) * 2021-04-07 2022-10-13

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109921T3 (es) * 1989-07-25 1998-02-01 Smithkline Beecham Biolog Nuevos antigenos y procedimientos para su preparacion.
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물

Also Published As

Publication number Publication date
KR20010090011A (ko) 2001-10-17
WO2000041463A3 (en) 2000-11-09
NZ512890A (en) 2003-09-26
CO5241355A1 (es) 2003-01-31
AU760574B2 (en) 2003-05-15
PL349347A1 (en) 2002-07-15
CN1391482A (zh) 2003-01-15
HUP0105070A2 (hu) 2002-04-29
CA2359110A1 (en) 2000-07-20
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (en) 2000-07-20
NO20013337L (no) 2001-08-17
EP1140163A2 (en) 2001-10-10
HK1041434A1 (zh) 2002-07-12
AR022250A1 (es) 2002-09-04
CZ20012544A3 (cs) 2002-01-16
JP2002534438A (ja) 2002-10-15
IL144186A0 (en) 2002-05-23
AU2100900A (en) 2000-08-01
TR200102024T2 (tr) 2001-12-21
ZA200105690B (en) 2002-09-25

Similar Documents

Publication Publication Date Title
TWI317735B (en) Methods and compositions for treating hepatitis c virus
BR9916893A (pt) Tratamento
TR199903053T2 (xx) Benzimidazol t�revleri.
BR0011433B1 (pt) Compostos de imidazoquinolinas substituídas com sulfonamida e sulfamida e composição farmaceutica cotendo os mesmos
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
HRP20040059B1 (en) Treatment of nail infections with no
AR002255A1 (es) Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.
EE05065B1 (et) Karbamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
PE61699A1 (es) Composicion farmaceutica de lamivudina
ES2041243T3 (es) Aplicacion de por lo menos un principio activo inhibidor o destructor de por lo menos un ser vivo unicelular o virus.
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
NO20055243L (no) Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS)
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.
AR025340A1 (es) Composiciones farmaceuticas
BR0009778A (pt) Composições antifúngicas de pseudomicina e métodos para utilização das mesmas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O E 7O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.